Effect of CB-154 therapy on the glucose tolerance, IRI and GH response to glucose administration in acromegaly.
Effects of CB-154 therapy on the glucose tolerance, IRI and GH responses to the oral glucose administration in 5 acromegalic patients with impaired glucose tolerance were examined. Glucose tolerance improved in all patients with a reduction in GH levels. Insulin secretion in response to the oral glucose administration was exaggerated in 3 patients, while it was supressed in 2 patients who had severely impaired glucose tolerance. After receiving CB-154 therapy, hyperresponsiveness of insulin observed in the 3 patients and a suppressed response in one patient were corrected to normal, while a low response in another stayed unchanged. This observation suggest that variable abnormalities in insulin secretion induced by the excess of GH improve with a decrease in plasma GH levels. However, the abnormal GH secretion in response to hyperglycemia persisted still after administration of CB-154 in spite of decreased basal plasma GH levels.
D000172:Acromegaly / Q000097:blood* / Q000188:drug therapy; D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use*; D005260:Female; D005947:Glucose / Q000494:pharmacology; D005951:Glucose Tolerance Test; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D007328:Insulin / Q000097:blood*; D007330:Insulin Antibodies; D008297:Male; D008875:Middle Aged
D007328:Insulin; D007330:Insulin Antibodies; D001971:Bromocriptine; D013006:Growth Hormone; D005947:Glucose